TEV-45779 (omalizumab biosimilar) / Teva - LARVOL DELTA

Study to Compare Efficacy and Safety of TEV-45779 With XOLAIR (Omalizumab) in Adults With Chronic Idiopathic Urticaria (clinicaltrials.gov) - P3 | N=608 | Completed | Sponsor: Teva Pharmaceuticals USA | Trial primary completion date: Sep 2023 ➔ Apr 2024

Trial primary completion date • Chronic Spontaneous Urticaria • Dermatology • Immunology • Urticaria

Study to Compare Efficacy and Safety of TEV-45779 With XOLAIR (Omalizumab) in Adults With Chronic Idiopathic Urticaria (clinicaltrials.gov) - P3 | N=608 | Completed | Sponsor: Teva Pharmaceuticals USA | Active, not recruiting ➔ Completed

Trial completion • Chronic Spontaneous Urticaria • Dermatology • Immunology • Urticaria

Study to Compare Efficacy and Safety of TEV-45779 With XOLAIR (Omalizumab) in Adults With Chronic Idiopathic Urticaria (clinicaltrials.gov) - P3 | N=600 | Active, not recruiting | Sponsor: Teva Pharmaceuticals USA | Recruiting ➔ Active, not recruiting

Enrollment closed • Chronic Spontaneous Urticaria • Dermatology • Immunology • Urticaria

Study to Compare Efficacy and Safety of TEV-45779 With XOLAIR (Omalizumab) in Adults With Chronic Idiopathic Urticaria (clinicaltrials.gov) - P3; N=600; Recruiting; Sponsor: Teva Pharmaceuticals USA; Not yet recruiting ➔ Recruiting

Clinical • Enrollment open • Chronic Spontaneous Urticaria • Dermatology • Urticaria